Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

计划入组 475 人 · 首次发布于 2020 年 7 月 13 日

ABC294640 in Treating Patients With Advanced Solid Tumors

计划入组 22 人 · 首次发布于 2011 年 12 月 8 日

OPAGANIB, A SPHINGOSINE KINASE-2 (SK-2) INHIBITOR IN COVID-19 PNEUMONIA: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN HOSPITALIZED ADULT SUBJECTS WITH SEVERE SARS-COV-PNEUMONIA- 2 POSITIVE

计划入组 0 人

Sphingosine

C₁₈H₃₇NO₂

sphingosine kinase 2 inhibitors (hematological cancer)

Opaganib

C₂₃H₂₅ClN₂O

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

RedHill's Opaganib Shows Promise in Overcoming Venetoclax Resistance in Chronic Lymphocytic Leukemia

RedHill's Opaganib Shows Promise for Weight Loss and Diabetes, Potentially Disrupting $100B Market

RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Preclinical Studies